Isomorphic Labs, an AI drug discovery company backed by DeepMind, is reportedly in talks to raise about $5 billion in new financing at a post-money valuation that could reach $50 billion — even though none of its drugs has yet entered human clinical trials. The company brings together a cross-disciplinary team with expertise in both AI and drug development, and has attracted a Nobel laureate to its scientific advisory board. Its core technology platform, IsoDDE, outperforms existing models such as AlphaFold 3 across multiple performance metrics, including the prediction of complex system structures. Isomorphic Labs operates on a business model that combines in-house development with partnerships with major pharmaceutical companies, and expects to launch its first human clinical trial by the end of 2026. The lofty valuation reflects the capital market's bet on whether AI can meaningfully improve the success rate of new drug development — a wager whose ultimate payoff remains to be validated by future clinical trial results.